---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031161"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:06:26.319184+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M

## Summary
- EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.
- GAAP net loss $11.0M ($0.23/share); non-GAAP adjusted loss $9.7M ($0.20/share).
- Positive clinical data: ENVET-BE study shows 2.4x increased yield; BE-1 study 88% sensitivity, 99% NPV.
- Cash $24.9M after $11.6M Series B-1 preferred stock issuance; held CMS MAC Palmetto GBA MolDX meeting.
- First major #CheckYourFoodTube event with upfront contracted payment; revenue cycle management improving.

## SEC filing metadata
- accession: 0001493152-24-031161
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315224031161/0001493152-24-031161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315224031161/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031161
- JSON: https://secwatch.observer/filing/0001493152-24-031161.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.